Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: Results of the Southern Italy Cooperative Oncology study 0401

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 2, 2009, Pages 217-226

  Comella, Pasquale ^a   Massidda, Bruno ^b   Filippelli, Gianfranco ^c   Farris, Antonio ^d   Natale, Donato ^c   Barberis, Giuseppe ^e   Maiorino, Luigi ^f   Palmeri, Sergio ^g   Cannone, Michele ^c   Condemi, Giovanni ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c City Hospital   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

^e Villa Betania Hospital   (Italy)

^f San Gennaro Hospital   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

Author keywords

Capecitabine; Colorectal carcinoma; OXAFAFU regimen; Oxaliplatin; OXXEL regimen; Randomized trial

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLATINUM COMPLEX;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLON TUMOR; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTUM TUMOR; SURVIVAL; TIME;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE; RECTAL NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 65849108886     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-008-0454-7     Document Type: Article

References (37)

1. Becouarn Y, Ychou M, Ducreux M et al (1998) Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 16:2739-2744
2. Borner MM, Dietrich D, Stupp R et al (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20:1759-1766
3. Cassidy J, Tabernero J, Twelves C et al (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084-2091
4. Cassidy J, Douillard J-Y, Twelves C et al (2006) Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 94:1122-1129
5. Cassidy J, Clarke S, Diaz-Rubio E et al. (2007) XELOX vs FOLFOX4: efficacy results from XELOX-1/NO16966, a randomised phase III trial in first-line metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol Gastrointestinal Cancer Symposium (abstr 270)
6. Comella P, Massidda B, Filippelli G et al (2005a) Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol 16:878-886
7. Comella P, Natale D, Farris A et al (2005b) Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. Cancer 104:282-289
8. Comella P, Massidda B, Palmeri S et al (2005c) Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients. A Southern Italy Cooperative oncology group phase II study. Cancer Chemother Pharmacol 56:481-486
9. Cox DR (1972) Regression models and life tables. J R Stat Soc 34:187-202
10. Díaz-Rubio E, Sastre J, Zaniboni A et al (1998) Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 9:105-108
11. Díaz-Rubio E, Tabernero J, Gómez-Espaka J et al (2007) Phase III study of capecitabine plus oxaliplatin compared with continuousinfusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish cooperative group for the treatment of digestive tumors trial. J Clin Oncol 25:4224-4230
12. Ducreux M, Bennouna J, Hebbar M et al. (2007) Efficacy and safety findings from a randomised phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 170s (abstr 4029)
13. Feliu J, Salud A, Escudero P et al (2006) XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 94:969-975
14. Fischel J-L, Etienne M-C, Formento P, Milano G (1998) Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 4:2529-2535
15. Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil- leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147
16. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30
17. Goldberg RM, Sargent DJ, Morton RF et al (2006) Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American intergroup trial. J Clin Oncol 24:3347-3353
18. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
19. Grothey A, Jordan K, Kellner O et al. (2003): Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial. Proc ECCO 12, Eur J Cancer S90 (abstract # 295)
20. Hochster HS, Hart LL, Ramanathan RK et al. (2006) Safety and efficacy of oxaliplatin/Xuoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. Proc Am Soc Clin Oncol Annual Meeting 24, 18S (abstract 3510)
21. Kaplan ES, Meier P (1958) Non parametric estimation for incomplete observations. J Am Stat Assoc 53:557-580
22. Lévi F, Misset JL, Brienza S et al (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69:893-900
23. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115
24. Machover D, Díaz-Rubio E, De Gramont A et al (1996) Two consecutive phase II study of oxaliplatin (L-OHP) for the treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with Xuoropyrimidines. Ann Oncol 7:95-98
25. Mantel N (1966) Evaluation of survival data and two new ranks of order statistics arising in its considerations. Cancer Chemother Rep 50:163-170
26. Martoni AA, Pinto C, Di Fabio F et al (2006) Capecitabine plus oxaliplatin (XELOX) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pviFOX) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). Eur J Cancer 42:3161-3168
27. Mayer RJ (2007) Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 25:4165-4167
28. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
29. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-Life scores. J Clin Oncol 16:139-144
30. Pfeiffer P, Mortensen JP, Bjerregaard B et al (2006) Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 42:2738-2743
31. Porschen R, Arkenau H-T, Kubicka S et al (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group. J Clin Oncol 25:4217-4223
32. Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9:1053-1071
33. Salts LB, Clarke S, Diaz-Rubio E et al. (2007) Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol Gastrointestinal Cancer Symposium (abstract 238)
34. Sandomenico C, Filippelli G, Massidda B et al. (2006): Biweekly oxaliplatin plus Xeloda (OXXEL) versus oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus (OXAFAFU) in metastatic colorectal carcinoma (MCC): safety interim analysis of a Southern Italy Cooperative oncology group (SICOG) phase III trial. Proc Am Soc Clin Oncol 168 s (abstract 3590)
35. Twelves C, Gollins S, Grieve R, Samuel L (2006) A randomised crossover trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 7:239-245
36. Ward SE, Kaltenthaler E, Cowan J et al (2006) The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer 95:27-33
37. Zeuli M, Nardoni C, Pino MS et al (2003) Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 14:1378-1382